Loading organizations...
§ Private Profile · Harburger Schlossstr. 6-12, Hamburg, 21079, Germany
Biotechnology company developing gene therapy drugs for chronic musculoskeletal diseases like osteoarthritis and disc degeneration.
GeneQuine Biotherapeutics has raised $7.0M across 1 funding round.
Key people at GeneQuine Biotherapeutics.
GeneQuine Biotherapeutics has raised $7.0M in total across 1 funding round.
GeneQuine Biotherapeutics, also known as GQ Bio Therapeutics, is a Hamburg, Germany-based biotechnology company that develops gene therapy-based drugs for chronic musculoskeletal diseases such as osteoarthritis and intervertebral disc degeneration. The organization utilizes a proprietary high-capacity adenoviral vector platform designed to enable affected tissues to locally produce therapeutic proteins following a single injection. Operating with a global workforce of 16 employees, the enterprise has secured approximately $10.62 million in total funding to advance its clinical pipeline and expand its core technology. Its financial backing includes a Series A equity round led by Pacira BioSciences, alongside investments from High-Tech Gründerfonds and Noshaq SA. The company also maintains strategic development partnerships with Exothera and Baylor College of Medicine to support its lead candidate, GQ-303. GeneQuine Biotherapeutics was officially founded in 2012 by Kilian Guse.
GeneQuine Biotherapeutics has raised $7.0M in total across 1 funding round.
GeneQuine Biotherapeutics's investors include Ron Ellis, DO, MBA, Forbion, Dr. Martin Pfister, Gaëtan Servais, Samum Vermoegensverwaltungs.
GeneQuine Biotherapeutics has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $7M Series A | RON Ellis, DO, MBA | Forbion, DR. Martin Pfister, Gaëtan Servais, Samum Vermoegensverwaltungs | Announced |
Key people at GeneQuine Biotherapeutics.
GQ Bio Therapeutics GmbH (formerly GeneQuine Biotherapeutics) is a Germany-based biotechnology company founded in 2012, specializing in gene therapy for chronic musculoskeletal disorders like osteoarthritis and intervertebral disc degeneration.[1][2][3] It develops transformative treatments using its proprietary high-capacity adenoviral vector (HCAd) platform, which enables efficient delivery of large genes, high transduction efficiency, and scalable manufacturing.[2][3] The company's lead products include GQ-501, a HCAd vector expressing proteoglycan 4 (lubricin) and IL-1Ra for osteoarthritis, and GQ-401, targeting intervertebral disc degeneration with an undisclosed protein—both in preclinical stages.[3] With 16 employees, sites in Hamburg, Luckenwalde (near Berlin), and Liège (Belgium), GQ Bio serves large biotech, big pharma, and smaller biotechs via out-licensing, addressing unmet needs in prevalent diseases affecting millions.[2][3]
GQ Bio Therapeutics, originally founded as GeneQuine Biotherapeutics in 2012 (some sources note 2011), emerged from an independent foundation focused on gene therapy for musculoskeletal disorders.[2][3][4] Co-founder and CEO Kilian Guse, an industry veteran, leads the company, which has evolved from early R&D in Hamburg to a sharpened focus on its HCAd platform.[2][3] A pivotal moment came in May 2023 with the name change to GQ Bio Therapeutics, facility expansion to 750 sqm in Luckenwalde for vector production and preclinical work, and Guse's board appointment—signaling readiness for clinical trials.[2] Early traction includes partnerships with Pacira, Exothera, Baylor College of Medicine, and mSKIL, building momentum toward out-licensing its pipeline.[3]
GQ Bio rides the gene therapy boom for musculoskeletal diseases, where traditional treatments fail to modify disease progression amid aging populations and rising osteoarthritis/disc degeneration prevalence.[1][3] Timing aligns with advances in viral vectors post-2023 approvals (e.g., for other indications), favoring scalable platforms like HCAd amid manufacturing bottlenecks plaguing competitors.[2] Market forces include surging demand for one-time therapies in orthopedics—a $10B+ addressable market—and EU funding for German biotech hubs.[1][2] GQ Bio influences the ecosystem by pioneering high-capacity vectors, potentially enabling combo-gene therapies and out-licensing to pharma giants, while its Berlin/Liège expansion bolsters Europe's biotech corridor.[2][3]
GQ Bio is poised for clinical trial entry with GQ-501/GQ-401, leveraging HCAd scalability to attract big pharma partnerships or acquisition—watch for Phase 1 data in 2026-2027.[2][3] Trends like AI-optimized vectors and combo-gene delivery will amplify its edge, while regulatory tailwinds in Europe propel growth amid global musculoskeletal therapy gaps. Its influence may evolve from preclinical innovator to licensed platform leader, transforming chronic disease management much like early gene therapy pioneers reshaped rare diseases—positioning it as a key player in biotech's next wave.[2][3]
